Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display promising therapeutic efficacy in NTRK-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Qing-Xiang, Zhao, Wen-Jun, Wang, He-Yue, Zhang, Lei, Qin, Lan, Han, Jian-li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176450/
https://www.ncbi.nlm.nih.gov/pubmed/37188179
http://dx.doi.org/10.3389/fonc.2023.1123812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176450/
https://www.ncbi.nlm.nih.gov/pubmed/37188179
http://dx.doi.org/10.3389/fonc.2023.1123812

Ejemplares similares